Estrella Immunopharma, Inc. (ESLA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ESLA
- Company Estrella Immunopharma, Inc.
- Price $0.53
- Changes Percentage -17.8
- Change -0.1139
- Day Low $0.51
- Day High $0.65
- Year High $3.15
- Year Low $0.68
- Market Cap $31,371,742
- Price Avg 50 EMA (D) $0.85
- Price Avg 200 EMA (D) $1.28
- Exchange NASDAQ
- Volume 8,171
- Average Volume 40,564
- Open $0.65
- Previous Close $0.64
- EPS -0.25
- PE -2.99
- Earnings Announcement 2026-12-02 12:00:00
- Shares Outstanding $42,665,228
Company brief: ESTRELLA IMMUNOPHARMA, INC. (ESLA )
- Healthcare
- Biotechnology
- Dr. Cheng Liu Ph.D.
- https://www.estrellabio.com
- US
- N/A
- 09-14-2021
- US2975841048
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.